Colour contrast sensitivity in ocular hypertension. A five-year prospective study.

摘要: Glaucoma is one of the most common causes blindness in world, and it important that screening tests as well treatment possibilities are improved continuously. A reliable but more rapid test than those already available would be great interest. In addition, new effective options valuable. The aims present thesis were to evaluate reliability a peripheral colour contrast sensitivity tool for glaucoma gain information on latanoprost, recently developed prostaglandin analogue, treatment.Colour was analysed with system described by Arden co-workers, using computer controlled monitor. objects central letters standard optotype subtending visual angle 3° . For test, object contrasting annulus concentric fixation spot. had radius 12.5° extramacular field width 1°. letter or relation background could changed, threshold value obtained protan, deutan tritan axes.In study patients, ocular hypertensive patients normals, found distinguish from normals. However, difficult find cut-off point if used test.In five-year prospective not clearly predict which develop not, given Herrrifield Test golden standard. change over time protan axis may, however, indicate development. screening, necessary know whether other eye diseases such diabetes cataract affect outcome. Therefore, influence also studied.Diabetes type II both sensitivity, being affected one. axis, seemed correlate degree diabetic retinopathy, indicating possibility functional retinopathy.Cataract, even moderately developed, sensitivity. Central poorer pseudophakic eyes normal eyes. Thus, moderate severe must considered screening. choice material IOL may importance postoperative sensitivity.The analogue latanoprost effectively reduces IOP at original concentration 0.005%. several need additional treatment. effect pilocarpine combination studied. When added there an reduction intraocular presure (IOP) (7.4%), when pronounced (142%). seems can combined treatment.In certain eyes, increased iris pigmentation seen side-effect latanoprost. This dose-dependent. 0.005% compared lower concentration, 0.001%. Latanoprost 0.001% reducing IOP. sufficiently have potential clinical use many patients. gave lOP 35% after four weeks treatment, agreement earlier results. was, surprisingly 27.7%.